An industry update: what is new in the field of therapeutic delivery this month?
The present industry update covers the period of 1-30 November 2016, with information sourced primarily from company press releases, regulatory and patent agencies, scientific literature and various news websites. There was positive news on the clinical trials front for both EyeNovia and Glaxo SmithKline, but this month also saw Innocol release disappointing Phase IIb results for its Cogenzia product. In regulatory news, it was announced that the US FDA indicated that EyeGate may use the 510(k) De Novo Path for their device, the Ocular Bandage Gel. Also this month, Glaxo SmithKline announced that it filed a regulatory submission with the FDA for its novel triple-combination therapy product, utilizing its Ellipta® inhaler.